QUÉBEC CITY, June 14, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that Jose M. Garcia, MD, PhD, of the Baylor College of Medicine and the Michael E.
DeBakey VA Medical Center in Houston,
Texas, will be making an oral presentation on Phase 3
results for AEZS-130 as an oral diagnostic test for Adult Growth
Hormone Deficiency (AGHD), at the 94th ENDO Annual
Meeting and Expo which will be held June
23-26, 2012, in Houston.
| Abstract #584: |
"AEZS-130 (Macimorelin) - Stimulated GH Test: Validation of
a Novel Test for the Diagnosis of Adult Growth Hormone Deficiency
(AGHD)", J. M. Garcia, R. Swerdloff, C. Wang, M. Kyle, M.
Kipnes, B. Biller, D. Cook, K. Yuen, V. Bonert, A. Dobs,
M. Molitch, G. Merriam. |
| |
|
| Date and time: |
Monday, June 25, 2012, at 11:15 am (Central) |
| Session: |
CLINICAL − What's New in Diagnosis & Treatment of GH
Dysfunction? |
| Venue: |
Theater A, George R. Brown Convention Center, Houston,
Texas |
About AEZS-130
AEZS-130, a ghrelin agonist, is a novel orally-active small
molecule that stimulates the secretion of growth hormone. The
Company has completed a Phase 3 trial for use as an oral diagnostic
test for AGHD. AEZS-130 has been granted orphan drug designation by
the FDA for use in this indication. Aeterna Zentaris owns the
worldwide rights to AEZS-130.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.